Drugs that act on both GPCRs and kinases: Potentiation of effects, side effects and general aspects of drug pleiotropy

preprint OA: closed
Full text JSON View at publisher
Full text 2,890 characters · extracted from oa-doi-fallback · click to expand
This is a preprint and has not been peer reviewed. Data may be preliminary. Drugs that act on both GPCRs and kinases: Potentiation of effects, side effects and general aspects of drug pleiotropy Abstract Background: A drug designed for a specific target often interacts with multiple targets, either unintentionally or as part of its intended mechanism of action. This phenomenon has been called pharmacological pleiotropy or polypharmacology. There are key endogenous ligands such as ATP, GABA and glutamate, that act on various proteins in humans. Furthermore, several drugs act on multiple proteins without apparent structural similarity. G protein-coupled receptors (GPCR) and protein kinases are among the most important families of drug targets. The aim of this review analysis is to identify drugs with dual actions on GPCRs and kinases and clarify what is known about these actions. Approach: Data searches for ligands with affinity for both kinases and GPCRs were conducted in the Drugbank and Pharos databases. Physiochemical properties of selected compounds were identified using the rdMolDescriptors module from RDKit. A detailed literature search was conducted in search engines such as Google Scholar and Medline, to identify pleiotropic compounds with both GPCR and kinase affinity. Outcome: 34 compounds were identified to interact with proteins within both the kinase and GPCR protein families. Notable examples included the drugs loratadine, terfenadine, clozapine, thioridazine, aripiprazole, fluspirilene, sorafenib, dasatinib, and fasudil. Conclusions: Drug pleiotropy among GPCRs and kinases is a commonly occurring phenomenon. Structural factors that may contribute to pleiotropy include chemical similarity to endogenous ligands, lipophilicity, and planarity of chemical structure, which may guide the development of drugs with intentional multi-target effects. While pleiotropy presents challenges in ensuring specificity, it also creates opportunities for innovative therapeutic strategies if strategically applied. Information & Authors Information Version history Copyright This work is licensed under a Non Exclusive No Reuse License. Collection Authors Metrics & Citations Metrics Article Usage 271views 102downloads Citations Download citation Hampus Ljunggren, Aleksandr Sokolov, Flavio Ballante, et al. Drugs that act on both GPCRs and kinases: Potentiation of effects, side effects and general aspects of drug pleiotropy. Authorea. 31 December 2025. DOI: https://doi.org/10.22541/au.176718976.62475551/v1 DOI: https://doi.org/10.22541/au.176718976.62475551/v1 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00